price month
 close
initi outperform target price
time tavr market leader ew one
highest-convict idea view size long-term tavr market
strength posit disrupt market underappreci
street primari driver stock least come two
three year longer expect low-risk lr trial
success march estim indic approxim
doubl ew offset potenti impact new
competit next two three year volatil
potenti everyon believ ew significantli outperform
univers next month recommend stock current level
ew lead market third- fourth-gener system make
compani hard catch believ new first- second-gener
tavr system face domin clinic matur tavr portfolio
ew broader indic includ younger lr patient largest
fastest-grow segment market come three five year
expect reach market
respect addit potenti limit limit
high-risk patient patient ew also like continu lead
new tavr center typic start proven market leader
view mitral-rel concern buy opportun mitral
repair replac import lt opportun structur heart
repres sale
estim therefor view mitral-rel concern buy
opportun ew
valuat target price base ebitda estim
bil ew current multipl ntm ebitda
risk includ key product approv delay unexpect chang
coverag tavr greater-than-expect share loss potenti new
litig regulatori issu
valuat metric
number share
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
mariu zoican univers toronto rotman school manag
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
global manufactur provid
medic devic equip structur valvular heart
diseas critic care
one-year valuat scenario base
ev/ebitda ebitda
scenario base emerg segment deliv
growth high-growth segment grow growth
grow
one-year valuat grey scenario base
ev/ebitda grey ebitda
grey scenario base emerg segment deliv
growth high-growth segment grow growth
grow
 close
mariu zoican univers toronto rotman school manag
initi coverag ew outperform target
price ew top pick one highest-convict idea outperform rate
base long-term impact size larg expand ww tavr market
believ remain underappreci street ew leadership
posit particularli market enabl compani sustain midteen
compound-annual-growth-rate ww tavr sale longer ew high-growth profil
sensit quarterli result make stock volatil therefor potenti
everyon high degre convict compani significantli
outperform univers come month recommend stock
street continu underappreci lt tavr analysi indic ew
manag remain conserv side see ww tavr
market exceed bil bil pleas see slide
industri report disrupt alpha detail tavr market estim
compar manag recent updat long-term view bil bil
period respect street remain roughli in-lin howev
debat continu whether low-risk indic expect approv
significantli expand market estim indic approxim
doubl address market would like repres signific catalyst
growth ew beyond
figur analysi indic upsid potenti street lt tavr
compani data credit suiss estim pleas see sector launch report disrupt alpha detail tavr market
signific larger lt market stock estim everi bil
addit lt tavr market equat stock assum market share
current increment margin discount target multipl
discount rate impact could even greater per extent ew
abl maintain signific share posit next three five year pleas
mil preval ssa mm ww tavr market bil baseblu skygrey skyww tavr volum prev mm base case call ww tavr procedur compound-annual-growth-rate penetr base ww tavr market estim preval ssasto mil ww current penetr decliningsteadili rise mariu zoican univers toronto rotman school manag
ew robust clinic profil leadership posit signific
challeng new entrant deep
relationship mani tavr center base breadth
intervent cardiolog devic transcathet vs surgic compani provid
 coronari stent abt mitraclip mitral repair bsx watchman left atrial
appendag closur said compani come market limit
clinic indic like remain case least first
month therefor lotu portico tavr system
compet entrench market leader ew high-risk hr
patient ew also continu expand penetr intermediate-
risk ir late lr patient well assum approv
addit limit approv indic anoth import relat competit
barrier entri face new entrant tavr market new center continu
open ramp clinic team treat increas number patient
center typic inclin implant clinician initi focu train
earli adopt one valv system market-lead tavr system
receiv feedback convers clinician expert
degre competit advantag ew rel past
year given new system enter market initi disadvantag term
label approv indic would surpris new entrant opt
invest time train ramp devic would abl treat
subset patient elig tavr
background detail tavr indic base convers clinician
expert peer-review literatur sever symptomat aortic stenosi ssa
estim hr indic high-risk patient includ patient unabl surviv open
heart surgeri inoper patient repres patient
diseas said hr current tavr volum hr ir
intermediate-risk patient two approv indic unit
state hr also matur easiest indic tavr
mostli due surgeon want perform open-heart surgeri hr patient
anymor tavr demonstr clinic safeti efficaci howev lr
approv address patient popul effect doubl hr
effect repres address market believ much
rapid growth tavr driven treatment lr patient
refer risk context tavr express level mortal risk
given patient face treat open surgeri put anoth way high-risk patient
suffer ssa assess greater risk surviv surgeri
global manufactur provid medic devic
equip structur valvular heart diseas critic care target price
base ebitda estim bil ew current
multipl ntm ebitda risk includ key product approv delay unexpect
chang coverag tavr greater-than-expect share loss potenti new
litig regulatori issu
addit detail pleas see industri report disrupt alpha
mariu zoican univers toronto rotman school manag
question face ew
low-risk indic meaning catalyst
ew
believ lr indic signific growth driver ew
beyond inoper high- intermediate- low-risk patient popul ssa
wide discuss review estim account lr account
around half total patient popul includ detail tavr market model
sector launch piec titl disrupt alpha look simpl math
assum bil tavr market current penetr ew estim
penetr would impli total potenti market figur
bil reflect penetr much larger current street
estim includ said estim ww tavr market
gener bil new revenu next three year bil
next seven year owe ew signific market posit clinic head start
key indic ir lr current market share believ
least new revenu bil accru compani
would doubl ew ww tavr revenu bil bil given
current consensu estim ww tavr market total remain bil
believ ew larg long-term potenti market valu price
current level estim increment bil project tavr market
sale would equat per share upsid stock assum market share
current increment margin discount target multipl
discount rate
figur analysi sensit ew chang tavr estim
compani data credit suiss estim note rational behind use ebitda multipl discount target multipl
base view ew current valuat may alreadi partial reflect expect upward revis long-term estim
estimate tavr market higher mm except per share data endhigh end project tavr market ew market share project ebit discount cs target multipl target /share impact mariu zoican univers toronto rotman school manag
term background one way tavr market differenti
market step-wis approach patient indic clear
first tavr system evalu approv patient
prohibit high risk death result open surgeri expect
surviv open-heart surgic procedur replac stenot calcifi aortic heart
valv devic prove effect patient fda approv evalu
patient high risk mortal due surgeri clear diagnosi
sever symptomat aortic stenosi ssa carri untreat mortal risk
month effect therapeut altern valv replac
step-wis clinic regulatori program enabl manufactur evalu
clinic safeti efficaci high risk intermedi risk patient expect
result two larg random multicent clinic trial march
ew evolut low-risk evalu use tavr
mariu zoican univers toronto rotman school manag
expect meaning measur gain temper lotuss limit initi
indic rapidli expand address market ew
sought enter market time face fair share
technic clinic challeng complet pivot studi
expect receiv approv launch lotu tavr
system expect reach analysi expect
gain share base reach
 tavr center end approv treat high-
risk inoper patient total ssa patient popul around
one-third current approv indic patient unit state expect
gain approv broader indic lotu subsequ
introduc second valv acquir symeti well
put asid notabl differ featur clinic perform among lotu
sapien ew evolut long term believ
like place system market howev believ best
straightforward way project potenti share gain stage
follow lotuss expect indic valv limit
total sass patient popul current one-third address market
approv indic high-risk inoper intermedi risk said
lr indic approv ew hr segment would
effect drop around address market beyond
key limit combin entrench posit ew market
give us confid ew abl continu grow tavr sale mid-
teen compound-annual-growth-rate longer
figur analysi launch bsx lotu tavr
importantli view bsx tavr share also conting upon real-world
rate perman pacemak placement lotu clinic histori
higher averag earli studi recent smaller cohort
patient versu mid-singl upper-singl digit ew sapien tavr valv
mdt evolut
analysi lotu tavr procedur center lotu grey total procedur center lotu high-risk indic current treat patient indic current risk indic current high risk grey high risk intermedi risk grey intermedi risk lotu tavr sale mil grey lotu tavr sale mil lotu tavr sale mil base market tavr market mariu zoican univers toronto rotman school manag
 tavr perform tavr revenu growth
consensu expect key stock driver addit manag
commentari around tavr market procedur growth market share therapi adopt
exceed previous issu guidanc rais guidanc around tavr would also
clinic trial data favor clinic trial data relat compani variou clinic
program tavr mitral tricuspid also key driver
low-risk trial data trial low-risk data expect
present march american colleg cardiolog meet fda
approv like late
product clinic trial provid brief overview compani key
recent launch product perform product commerci adopt
drive futur revenu growth key catalyst
sapien ultra ew receiv ce mark approv novemb
expect implement control roll-out strategi europ
compani also expect regulatori approv sapien ultra
system featur sapien ultra valv heighten outer skirt
deliveri system incorpor on-balloon design
centera ew self-expand tavr system receiv ce mark
februari compani current implement target
commerci introduct europ also initi pivot trial
sever symptomat aortic stenosi patient intermedi risk open-
heart surgeri centera septemb put approv
late estim
cardioband tricuspid valv reconstruct system treatment
tricuspid regurgit limit number patient treat
commerci europ suppli constraint improv throughout
 compani expect pivot trial initi
late put approv estim
cardioband deliv via transfemor approach design
reduc tricuspid regurgit annular reduct featur
design implant techniqu cardioband mitral system
cardioband cardioband ce mark approv mitral regurgit
receiv septemb ew treat patient eu
commerci data present
manag paus activ trial assess
coapt
pascal manag expect launch pascal europ
 compani approv pivot trial clasp
studi patient primari mitral regurgit expect
harpoon ew receiv ce mark approv harpoon beat heart
mitral valv repair system decemb eu launch put
hold pend review patient complic expect
reintroduc
mariu zoican univers toronto rotman school manag
increas competit ww tavr market lead faster-than-expect share
eros price pressur addit failur execut pipelin opportun
expand new therapi may result compani fail achiev long-term
financi goal final on-going patent litig could result costli time-
consum litig potenti delay product develop commerci
mariu zoican univers toronto rotman school manag
overview major busi line
ew organ four main segment transcathet aortic valv replac
transcathet mitral tricuspid therapi surgic heart valv technolog critic
care figur figur overview major busi line size
geograph mix growth profil well primari competitor key product
figur sale profit major busi line
sale geographi
profit geographi
compani data credit suiss estim profit major busi line disclos compani
figur overview major busi line
op margin cagrcomp key productstavrtranscath aortic valv replac treatment symptomat sever aortic forwardmdt abtsapien line tavr productstmtttranscath replac repair treatment mitral tricuspid regurgit tot forwardmdt abtpasc cardioband forma evoqu line mitral tricuspid systemssurg structur heartsurg heart valv replac includ aortic mitral valv product replac repair diseas malfunct heart forwardmdt abtharpoon perimount inspiri resilia line surgic tissu heart valv productscrit carehemodynam monitor system measur heart function blood pressur monitor forwardicui deltex medicalflotrac clearsight line hemodynam monitor system truwav pressur monitor mariu zoican univers toronto rotman school manag
ew estim coverag univers
contribut mitral
tricuspid repair
leadership tavr
beatabl
driven margin
figur coverag univers glanc
growth org growth y/i y/i y/i growth ratingpricetarget pricedownsidemultiplemethodologylarg cap med-techbaxt lifesci scientif biomet cap med-techwright medic lifesci mariu zoican univers toronto rotman school manag
figur analysi indic potenti upsid lt tavr expect
expect
expans tavr
indic
beyond
estim much
bil
importantli
level estim
elig
patient treat
consider room
analysi
increment bil
per share
mil preval ssa mm ww tavr market bil baseblu skygrey skyww tavr volum prev mm base case call ww tavr procedur compound-annual-growth-rate penetr base ww tavr market estim preval ssasto mil ww current penetr decliningsteadili rise adoptionincrement tavr market size market share tavr market vs street expectationsequ per share increment sharehold mariu zoican univers toronto rotman school manag
figur higher thv mix drive margin perform bp
tavr ew
busi
increas mix tavr
would like
figur best-in-class organ growth driven highest spend among
growth driven
among peer
fuel new
margin tavr mix total salestavr mix total salesoper margintavr mix drive margin growth compound-annual-growth-rate averag spend sale averag total sale growth compound-annual-growth-rate cap averagehighestorgan growth among peer driven mariu zoican univers toronto rotman school manag
figur transcathet mitral tricuspid therapi bil ww
opportun
growth driven
indic
figur wide-rang transcathet mitral tricuspid tmtt valv
cardioband mitral transcathet devic reduc mitral regurgit annular
pascal expect eu launch clasp iid dmr pivot trial enrol
clasp iif fmr pivot trial initi expect late
harpoon launch eu launch hold pend review patient complic
multipl shot goal
mitral repair
replac
robust mitral
tricuspid pipelin
drive next leg
cardiaq eu launch expect launch
sapien transfemor approach valv deploy plan initi pivot trial late
evoqu transsept valv replac platform earli feasibl studi start
cardioband tricuspid transcathet devic reduc tricuspid regurgit annular
reduct ce mark april activ tr pivot trial initi late
forma resum treat patient signific function qualiti life
improv earli experi continu earli feasibl studi updat devic
size bil transcathet mitral tricuspid therapi representa larg market opportun mariu zoican univers toronto rotman school manag
target price reflect strength ew tavr leadership posit
strength ew posit
target price base ev/ebitda multipl estim
bil multipl roughli in-lin ew valuat ntm ebitda
outperform rate multipl base view size long-term
tavr market
underappreci street ew like abl continu grow tavr
busi midteen driven approv expand indic tavr
 estim approxim doubl ew
offset potenti impact new competit come two three year
stock rebound earn compani fell short street
expect tavr sale intermediate-risk approv ew stock current
trade signific premium large-cap med-tech peer group owe strong
organ growth profil market leadership ww tavr market grow
doubl digit remain significantli under-penetrated view
disrupt market
one-year valuat scenario base
ev/ebitda ebitda
scenario base emerg segment deliv growth high-growth
segment grow growth grow
grey one-year valuat grey scenario base
ev/ebitda grey ebitda grey
scenario base emerg segment deliv growth high-growth
segment grow growth grow
yr sd vs yr mariu zoican univers toronto rotman school manag
risk target price rate follow
increas competit tavr market slow growth edward
lifesci market leader rapidli grow tavr market current
compet larg competitor boston scientif
europ potenti time well increas
competit compani could result increas price pressur
market share loss would like put pressur ew oper perform
addit market show sign deceler due penetr
issu could materi advers effect oper perform
potenti delay failur clinic timelin regulatori approv
reimburs pipelin product compani robust product
pipelin across
execut pipelin
opportun expand new therapi may result compani fail achiev
long-term financi goal product becom obsolet custom switch
competit product could materi impact compani
revenu profit unfavor result unforeseen circumst
relat ew clinic program could result delay failur regulatori
approv new product plan modif indic expans
exist product addit chang insur coverag polici reimburs
regulatori chang relat compani product procedur could
neg affect busi line potenti advers event challeng
materi affect oper cost potenti sale growth compani
product patent litig exposur product liabil claim patient other
may result costli litig loss revenu product recal brand impair
could materi advers effect ew addit patent infring
claim compani initi compani third parti could also
result costli time-consum litig potenti delay product develop
market ew current engag patent litig outperform-r
ew sapien sapien heart valv germani bsx
lotu valv sapien ew launch sapien ultra valv
germani result preliminari injunct bsc chose implement
german court expect hold full hear merit disput
patent ep decemb district court rule ew
award damag ew expect pay juri award
new fda quality-rel issu challeng relat associ
remedi ew product regul fda non-compliance
regulatori requir could result potenti warn letter warn letter
could result signific modif compani oper potenti recal
inabl obtain futur pre-market approv remov current product
market remedi warn letter consist comprehens
plan correct action could drawn materi advers effect
compani term addit remedi cost potenti delay
disrupt product approv avail compani current
outstand warn letter fda
mariu zoican univers toronto rotman school manag
ew current price emb long-term sale growth expect
assum annual margin improv
run market-impli scenario use forecast holt dcf
assum annual margin improv solv
sale compound-annual-growth-rate requir justifi current price ew
sensit tabl figur help quantifi impact increment margin
growth ew valuat sensit top-lin growth everi increment
ad per share vs per share ad increment margin
bpsassumpt downsidewithin upsideew valuat sensit top line growth everi increment ad per share vs per share ad increment marginsebitda margin base cs research kept constant growth base cs research solv increment sale compound-annual-growth-rate requir get current price explicit forecast holt methodolog calcul termin valu fade return capit growth toward cost capit growth lifesci corp ew illustr price assumptionsvalu sensit analysisat current share price sale ebitda marginsforecasthistor year medianebitda margin step assum annual margin increas sale growthmarket impli growthhistor year mediansal growth step solv lt sale compound-annual-growth-rate requir get current cfroimarket impli cfroidiscount ratehistor year mediancfroi base cs forecast deriv long term assumpt market impli expectationsc researchc mariu zoican univers toronto rotman school manag
peer global databas captur uniqu inform compani within
credit suiss coverag univers base relationship compani
custom supplier competitor databas built research analyst
insight regard relationship credit suiss cover compani global
compani form core peer databas also includ relationship
stock coverag inform see novemb
mariu zoican univers toronto rotman school manag
financi statement project
mm except per share gross op incom interest exp inc inc exp pre-tax incom tax ep dilut dilut growth rate incom mariu zoican univers toronto rotman school manag
mm except per share cc ww- nm- us- nm- nmnmnmnmnm- nmnmnmnmnm- nm- ous- nm- cc growthsurg structur heart cc cc sale cc growth organ cc mariu zoican univers toronto rotman school manag figur edward lifesci balanc sheet
mm except per share short-term prepaid total current pp intang long-term total non-curr total st debt- account payabl acrd current liabilities- total current lt long-term total non-curr total common addit contribut retain accum comp inc treasuri total stockhold total liabil balanc sheet inventori account payabl total net debt total debt mariu zoican univers toronto rotman school manag figur edward lifesci statement flow
mm except per share flowsnet incom depreci stock base non-cash chang work payabl acrd asset cf oper y/i flowscapit purchas intang chang other- use y/i flowsdividends- proce payment net stock issuanc purchas treasuri y/i fx net chang begin end cf convers convers mariu zoican univers toronto rotman school manag
compani mention price
matt miksic vik chopra certifi respect compani secur individu analyz view express
report accur reflect person view subject compani secur part compens
directli indirectli relat specif recommend view express report
